OBJ isn't going to disappear, but at any M.C. of $65mill it's more than a little hard justify.
Another poster Madamswer made the following comment on another stock -
"
If you torture any data set hard enough, you can get it to confess to any crime of your choosing."
That's what seems to be happening here. JTA reported that the conference call stated; 2-3 quarters to "cash flow positive", however skypilot reported that statement as 2-3 quarters to be CLOSE TO OPERATING COSTS.
A huge difference, more so in a licensing company.
It also made me consider the 500% improvement in surface hygiene from Cleaning Products call, P&G's suite of clenaing hygiene products advertise "Kills 99.9% of known bacteria", How does one improve that by 500%? Someone's telling Furphies.
BG data is really not that impressive, their best score is in the test subjects' personal pain rating. And that's undermined by a resultant 50% reporting skin irritation. Still no confirmed partner for commercialisation.
Shavers are off the board, Hair is not soon. Cleaning is not soon. Pharma is nowhere to be seen. Coty is not soon. Oral Hygiene thrown out by Reckitt (anybody ask why? There'd be good thing to know) and now reverted back to starting point with P&G.
So that means all OBJ have is P&G skin care... for whom the royalty is 2-3% of NET PROFIT;
another piece of data that can be tortured. Who determines the NET PROFIT, it'll be P&G, so don't expect huge royalties.
Some comments were made on the market in China as ostensibly 3.5 million people IF 5% of market share. 5% is huge in this field. (
@makattack, before you quote quora.com, please realise it's open to anyone to post, similar to facebook, e.g. you can ask where Theresa May buys her underwear and get an answer on quora.... use a reputable source, 33% of Chinese are absolutely NOT NOT NOT as rich as people in developed counties)...the logical conclusion is that royalties from China will be much, much lower and later than HC true believers would have you think.
So with all that in mind, OBJ is working toward OPERATING COST cut-even, so there's a coin flip whether another CR will be needed in the future for Admin and R&D and Marketing costs.
The revenue going forward, next 12 months, is doubtful to exceed 5% of market cap, and not even this management is suggesting any profits. That all spells more SP pain, I believe; unless speculators taking a sentiment punt maybe push it up.
(20min delay)